Eli Lilly (LLY) is in advanced negotiations to acquire privately held biotech Kelonia Therapeutics in a deal valued at more than $2 billion, according to people familiar with the matter cited by The Wall Street Journal. If discussions conclude successfully, an agreement could be announced as soon as Monday, with the final consideration likely to include milestone payments tied to future development progress.
Boston-based Kelonia is developing a next-generation CAR-T cell therapy platform designed to eliminate the need for pre-treatment chemotherapy and simplify the complex, patient-specific manufacturing process associated with conventional CAR-T treatments. Its lead program targets multiple myeloma and received FDA clearance earlier this year to begin a Phase 1 safety trial in up to 40 participants. According to PitchBook data, Kelonia has raised less than $60 million in total funding and was last publicly valued at just over $100 million in April 2022. Lilly’s willingness to pay north of $2 billion represents a significant premium, signaling a strategic bet to lock in a potentially disruptive “chemo-free” cell therapy platform at an early stage rather than waiting for Phase 2 data to drive the price even higher.
The proposed acquisition is the latest example of Lilly deploying the enormous cash flow generated by its GLP-1 franchise to aggressively replenish its pipeline. In just the first three months of this year, Lilly has already announced the acquisitions of Orna Therapeutics for up to $2.4 billion and Ventyx Biosciences for approximately $1.2 billion, pushing year-to-date deal spending close to the $10 billion mark. With Jaypirca currently its only commercialized blood cancer asset, absorbing Kelonia would directly strengthen Lilly’s foothold in cell therapy within a global oncology market estimated at roughly $240 billion.
However, a clear strategic rationale does not automatically equate to a comfortable margin of safety in the stock. Lilly currently trades at a price-to-earnings ratio of approximately 39x, a significant premium to both the S&P 500’s average of roughly 26x and the large-cap pharmaceutical sector average of around 23x. The narrative underpinning this valuation rests squarely on the explosive growth of its two GLP-1 heavyweights, Mounjaro and Zepbound—which saw sales surge 99% and 175%, respectively, in 2025, propelling Lilly’s stock to a cumulative gain of over 1,100% over the past decade. Yet, such a lofty multiple leaves razor-thin room for error.
Risks emanate from at least three directions. First, the patent cliff is unavoidable. Once core patents on Mounjaro and Zepbound expire, the inevitable influx of generics will erode Lilly’s revenue foundation. Second, the competitive landscape is tightening rapidly. Novo Nordisk has already launched an oral GLP-1 formulation that is accumulating substantial demand, while Pfizer is advancing its own long-acting injectable candidate. Lilly’s first-mover advantage is far from unassailable. Third, the acquired assets—including Kelonia—remain in early clinical stages. The inherently high failure rate of biopharmaceutical R&D means that Lilly’s diversification strategy, while directionally sound, remains a calculated gamble with no guarantee of clinical or commercial success.
Analyst opinion on Lilly’s current valuation is divided. BMO Capital Markets analyst Evan Seigerman captured the prevailing tension in a recent note, writing: “Lilly is attempting to build a bridge between the current glory of GLP-1 and an uncertain future. The problem is that the cost of that bridge is already reflected in the share price, and the other side of the bridge remains without clear landmarks.”
Ultimately, whether a 39x P/E is too high depends entirely on how much of a premium an investor is willing to pay for those “future options.” Lilly possesses one of the strongest cash flow engines in the pharmaceutical industry and is rightly converting near-term profits into long-term pipeline assets. But a high valuation is, in itself, a material risk: it requires GLP-1 sales growth, Kelonia’s clinical data, and post-merger integration to all unfold with near perfection. For investors prioritizing a margin of safety, waiting for a more attractive entry point or greater clarity from pivotal clinical readouts may be the more prudent course of action.
